Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Total Non-current Assets
All assets not expected to be converted to cash within one year.
Septerna, Inc.NASDAQ: SEPN
Total Non-current Assets · Q3 FY2026 · quarter ended Sep 2026
Total non-current assets falls 2.5% from a year ago
Total non-current assets stood at $112.06M at the end of Q3 FY2026, down 2.5% from a year earlier and down 34.3% from the prior quarter. Over 3 fiscal years it compounded at +252.5% a year.
Context
- Total non-current assets amounted to 18.1% of total assets at the end of Q3 FY2026, down 0.9 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -2.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 185.22M USD
- Year-over-year change
- +85.7%
- 3-year CAGR
- +252.5%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 185.22M | +85.7% |
| FY2024 | 2024-12-31 | 99.73M | +448.3% |
| FY2023 | 2023-12-31 | 18.19M | +330.1% |
| FY2022 | 2022-12-31 | 4.23M | — |
Total Non-current Assets vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 total non-current assets of $112.06M is the 2nd highest of the 7 companies compared; the peer median is $23.89M.
- Its year-over-year change of -2.5% is the 4th highest of 6, against a peer median of +20.5%.
- Total non-current assets amounts to 18.1% of total assets for SEPN, versus a peer median of 2.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $282.25M | — | — | 23.3% |
SEPNSepterna, Inc. | Sep 2026 | $112.06M | -2.5% | +252.5% | 18.1% |
| Jun 2026 | $53.39M | +211.4% | +42.0% | 3.7% | |
| Mar 2026 | $39.93M | +20.5% | +2.7% | 9.5% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $7.86M | +205.2% | +59.8% | 1.6% |
| Mar 2026 | $67K | -99.4% | -64.3% | 0.1% | |
| Mar 2026 | $5K | -95.5% | -90.1% | 0.0% | |
| Peer median (excluding SEPN) | $23.89M | +20.5% | +2.7% | 2.7% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.